在IDH突变质瘤的进展过程中,不断变化的细胞状态和瘤驱动因素
Jingyi Wu1,2,3, L Nicolas Gonzalez Castro2,4,5,6, Sofia Battaglia1,2,3
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nature cancer
|November 21, 2024
概括
通过改变细胞群和表观遗传驱动因素,IDH突变质瘤从缓慢生长发展到致命. 针对这些表观遗传变化的疗法为这些脑瘤提供了新的治疗可能性.
科学领域:
- 神经瘤学神经瘤学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 异酸脱酶 (IDH) 突变标志着一种已知进展至致命疾病的质瘤子集.
- 了解IDH突变质瘤的细胞层次和发育状态对于破译它们的进展至关重要.
- 正常的大脑细胞比较对于定义质瘤异常发育轨迹至关重要.
研究的目的:
- 为了描述IDH突变质瘤中的恶性细胞层次.
- 为了确定低级和高级质瘤中瘤细胞的发育状态.
- 阐明质瘤进展的表观遗传和遗传驱动因素.
主要方法:
- 低等级和高等级的IDH突变质瘤的单细胞染色质可访问性和基因表达概况.
- 将瘤细胞状态与正常脑细胞进行比较,以确定发育起源.
- 在瘤进展过程中对DNA甲基化模式和遗传变化的分析.
主要成果:
- IDH突变性质瘤最初来自缓慢循环的寡腺细胞原生细胞类细胞.
- 瘤进展包括由染色体重编程驱动的增殖神经原始细胞样群体的扩张.
- 从基于甲基化的转向基因驱动因素发生了转变,低度瘤中抑制了干扰素信号,高度瘤中破坏了干扰素信号.
结论:
- 这项研究解释了缓慢生长的IDH突变质瘤到致命恶性瘤的进展机制.
- 表观遗传变化,特别是DNA高甲基化及其对干扰素信号传递的影响,起着至关重要的作用.
- 研究结果表明,针对这些脑瘤的表观遗传基础的治疗策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Cancers Originate from Somatic Mutations in a Single Cell
11.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


